Quick Answer
Denali Therapeutics Inc. reported Revenue (ASC 606) of $0.00 for fiscal year 2025.
Denali Therapeutics Inc. Revenue (ASC 606) — Annual History
| Fiscal Year | Revenue (ASC 606) | YoY Change |
|---|---|---|
| 2025 | $0.00 | — |
| 2024 | $0.00 | -100.0% |
| 2023 | $330.53M | +214.6% |
| 2022 | $105.06M | +115.9% |
| 2021 | $48.66M | -85.5% |
| 2020 | $335.56M | +1174.9% |
| 2019 | $26.32M | -79.6% |
| 2018 | $129.10M | — |
| 2017 | $0.00 | — |
| 2016 | $0.00 | — |
Quarterly Revenue (ASC 606)
| Quarter Ending | Revenue (ASC 606) | YoY | QoQ |
|---|---|---|---|
| September 30, 2024 | $0.00 | -100.0% | — |
| June 30, 2024 | $0.00 | -100.0% | — |
| March 31, 2024 | $0.00 | -100.0% | -100.0% |
| September 30, 2023 | $1.27M | +588.6% | -99.6% |
| June 30, 2023 | $294.12M | +460.4% | +737.0% |
| March 31, 2023 | $35.14M | -16.6% | +18998.4% |
| September 30, 2022 | $184.0K | -96.5% | -99.6% |
| June 30, 2022 | $52.48M | +128.8% | +24.5% |
- The most recent figure is from Denali Therapeutics Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 26, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: